Characterization and Quality Control of Biopharmaceuticals Using the Multi-Attribute Method (MAM): Advantages and Challenges
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 1469
Special Issue Editor
Interests: mass spectrometry (MS); LC-MS, LC-MSMS; intact mass analysis; peptide mapping (PM); top-down sequencing (TDS); middle-up analysis; subunit analysis; analytical characterization; quality control (QC); post-translational modifications (PTMs); multi-attribute method (MAM); new peak detection (NPD); critical quality attribute (CQA); product quality attributes (PQAs); quality by design (QbD); biopharmaceuticals; monoclonal antibodies (mAb); cell and gene therapy (CGT); adeno-associated virus (AAV); biosimilar; glycosylation; deamidation; vaccines; MRNA; proteins; peptides; oligonucleotides; host cell proteins (HCPs); impurities; biomarkers; bioassays; bioactivity; potency; structure–activity relationship (SAR)
Special Issue Information
Dear Colleagues,
The biopharmaceutical industry is rapidly evolving, bringing complex biologics such as monoclonal antibodies (mAbs) and fusion proteins to the forefront of modern medicine. However, the intricate structures of these therapeutics pose significant challenges for characterization and quality control (QC), which traditional analytical methods often struggle to address. The Multi-Attribute Method (MAM) is emerging as a critical solution, offering detailed and accurate profiling of product quality attributes (PQAs) and streamlining QC workflows by consolidating multiple analyses into a single approach. Despite MAM’s advantages, adoption barriers remain, including the need for robust data analysis, regulatory acceptance, and standardized workflows.
Scope and Objectives of this Special Issue: This Special Issue compiles the latest advancements, applications, and insights regarding the MAM’s role within the biopharmaceutical sector, focusing on four primary areas:
- Advanced MAM Workflows: Innovative methodologies and case studies illustrating the MAM’s integration into biotherapeutic development and manufacturing;
- Regulatory Insights: Perspectives on the regulatory acceptance of the MAM and its alignment with current Good Manufacturing Practices (cGMPs);
- Technical Challenges and Solutions: In-depth discussions on technical hurdles encountered during MAM implementation, along with practical strategies to address them;
- Future Directions: Emerging trends and the evolving role of the MAM as the biopharmaceutical landscape continues to advance.
Conclusions: As the biopharmaceutical industry progresses, adopting sophisticated analytical tools like the MAM is vital for maintaining the rigorous quality and safety standards required for biologics.
This Special Issue will serve as a valuable resource for researchers, industry professionals, and regulatory stakeholders, providing a comprehensive look into MAM’s transformative potential. We hope that these contributions inspire continued innovation and collaboration, ultimately enabling the development of safer, more effective biotherapeutic products.
Dr. Jingzhong Guo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- analytical characterization
- critical quality attribute (CQA)
- the multi-attribute method (MAM)
- new peak detection (NPD)
- post-translational modifications (PTM)
- product quality attribute (PQA)
- peptide mapping (PM)
- quality by design (QbD)
- quality control (QC)
- structure–activity relationship (SAR)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
